Voyager Therapeutics(US:VYGR)2021-08-13 20:31Company Highlights - Voyager Therapeutics is focused on delivering the next generation of gene therapies[1] - The company is extending its cash runway into early 2023[5] Technology Platform - Voyager Therapeutics utilizes proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, and pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations[5] - The company is increasing platform investment to expand discovery of novel targeted AAV capsids and clinical application of vectorized antibodies[5] - TRACER AAV capsids offer superior transduction of targeted tissues enabling lower dose GTx using IV delivery to target CNS, cardiac, and skeletal muscle[7] - The company's vectorized mAb platform aims to achieve therapeutic antibody levels to CNS via IV delivery to overcome very low CNS penetration of traditional mAbs, with preclinical POC demonstrated with an anti-tau program and exploration into neuro-oncology indication[7] - Voyager Therapeutics is advancing best-in-class GTxs leveraging superior TRACER capsids across CNS indications, potentially allowing for IV administration, lower dosing, favorable safety, and superior CNS tissue distribution[7] - Multiple candidates show a 10-1000-fold improvement in CNS & spinal cord transduction compared to AAV9[10]